Alume Biosciences Publishes First-in-Human Bevonescein Nerve Imaging Data in Nature Communications
Alume Biosciences Publishes First-in-Human Data on Bevonescein for Nerve Imaging in Nature Communications Alume Biosciences, a late-clinical stage biotechnology company focused on improving surgical safety through nerve-illuminating technologies, has announced…
JCR Pharmaceuticals Completes Enrollment in JR-141 Phase III Trial
JCR Pharmaceuticals Completes Enrollment in Global Phase III Trial for JR-141 Targeting Hunter Syndrome JCR Pharmaceuticals Co., Ltd. (TSE 4552; JCR) has announced the successful completion of participant enrollment for…
OXLUMO® Now Reimbursed in Canada for PH1 Treatment
OXLUMO® (Lumasiran) Secures National Reimbursement in Canada for Treatment of Primary Hyperoxaluria Type 1 Alnylam Canada ULC has announced that OXLUMO® (lumasiran), a first-in-class RNA interference (RNAi) therapeutic, is now…
FDA Grants Accelerated Approval to Lynozyfic for Relapsed Multiple Myeloma
Regeneron’s Lynozyfic™ Secures FDA Accelerated Approval for Heavily Pretreated Multiple Myeloma Patients Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval…
Givastomig Shows Promise in 1L Gastric Cancer: I-Mab at ESMO GI 2025
I-Mab Presents Positive Phase 1b Data for Givastomig in Combination with Nivolumab and Chemotherapy in 1L Gastric Cancer at ESMO GI 2025 I-Mab (NASDAQ: IMAB), a U.S.-based global biotechnology company…
Asahi Kasei Pharma Launches Global Phase III Trial of ART-123 for CIPN Prevention
Asahi Kasei Pharma Initiates Phase III Clinical Trial of ART-123 to Combat Chemotherapy-Induced Peripheral Neuropathy Asahi Kasei Pharma Corporation has officially commenced drug administration in a pivotal Phase III clinical…
WHO Launches Drive to Boost Health Taxes, Save Lives
WHO Unveils “3 by 35” Health Tax Initiative to Combat NCDs and Boost Public Revenue The World Health Organization (WHO) has launched a bold and far-reaching global campaign aimed at…
Incyte Announces Inducement Grant Under Nasdaq Rule 5635(c)(4)
Incyte Grants Equity Awards to Incoming CEO Bill Meury Under Nasdaq Rule 5635(c)(4) Incyte Corporation (Nasdaq: INCY) announced the grant of equity inducement awards to Bill Meury, marking a key…
FDA Grants Accelerated Approval to Lynozyfic™ for Relapsed or Refractory Multiple Myeloma
FDA Grants Accelerated Approval to Regeneron’s Lynozyfic™ (linvoseltamab-gcpt) for Relapsed or Refractory Multiple Myeloma Regeneron Pharmaceuticals has secured a critical milestone in oncology drug development with the U.S. Food and…
FDA Grants Priority Review for WINREVAIR Label Update Based on ZENITH Trial
FDA Grants Priority Review to Merck’s WINREVAIR™ Based on Landmark ZENITH Trial Showing Dramatic Reduction in Morbidity and Mortality in PAH Patients Merck (NYSE: MRK), operating as MSD outside the…
Gilead Advances in HIV Market With Twice-Yearly Yeztugo, Leaving GSK Behind
Gilead Targets HIV Prevention Dominance With Twice-Yearly Yeztugo as GSK Mounts a Defense Gilead Sciences is taking a bold step to further entrench itself as the dominant force in HIV…
Lupin Unveils New Consumer Healthcare Arm: LupinLife
Lupin Launches LupinLife as Independent Subsidiary to Strengthen Focus on India’s Self-Care Market Global pharmaceutical leader Lupin Limited has announced a significant strategic move to bolster its consumer healthcare operations.…